Literature DB >> 32852684

Erenumab efficacy in highly resistant chronic migraine: a real-life study.

Umberto Pensato1, Valentina Favoni2, Alessia Pascazio1, Matteo Benini1, Gian Maria Asioli1, Elena Merli1, Calogero Calabrò1, Pietro Cortelli1,2, Giulia Pierangeli1,2, Sabina Cevoli3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32852684     DOI： 10.1007/s10072-020-04658-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  7 in total

Review 1.  CGRP Targeting Therapy for Chronic Migraine-Evidence from Clinical Trials and Real-world Studies.

Authors:  Yen-Feng Wang; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2022-05-14

2.  Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men.

Authors:  Raffaele Ornello; Carlo Baraldi; Simona Guerzoni; Giorgio Lambru; Matteo Fuccaro; Bianca Raffaelli; Astrid Gendolla; Piero Barbanti; Cinzia Aurilia; Sabina Cevoli; Valentina Favoni; Fabrizio Vernieri; Claudia Altamura; Antonio Russo; Marcello Silvestro; Elisabetta Dalla Valle; Andrea Mancioli; Angelo Ranieri; Gennaro Alfieri; Nina Latysheva; Elena Filatova; Jamie Talbot; Shuli Cheng; Dagny Holle; Armin Scheffler; Tomáš Nežádal; Dana Čtrnáctá; Jitka Šípková; Zuzana Matoušová; Lucia Sette; Alfonsina Casalena; Maurizio Maddestra; Stefano Viola; Giannapia Affaitati; Maria Adele Giamberardino; Francesca Pistoia; Uwe Reuter; Simona Sacco
Journal:  Front Neurol       Date:  2021-12-16       Impact factor: 4.003

3.  Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany.

Authors:  Andreas Straube; Philipp Stude; Charly Gaul; Katrin Schuh; Mirja Koch
Journal:  J Headache Pain       Date:  2021-11-06       Impact factor: 7.277

Review 4.  Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes.

Authors:  Eleonora De Matteis; Simona Sacco; Raffaele Ornello
Journal:  Ther Clin Risk Manag       Date:  2022-04-05       Impact factor: 2.423

5.  Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.

Authors:  Umberto Pensato; Carlo Baraldi; Valentina Favoni; Davide Mascarella; Eleonora Matteo; Giorgia Andrini; Maria Michela Cainazzo; Pietro Cortelli; Giulia Pierangeli; Simona Guerzoni; Sabina Cevoli
Journal:  Cephalalgia       Date:  2022-02-09       Impact factor: 6.075

Review 6.  Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments.

Authors:  George R Nissan; Richard Kim; Joshua M Cohen; Michael J Seminerio; Lynda J Krasenbaum; Karen Carr; Vincent Martin
Journal:  J Clin Med       Date:  2022-07-27       Impact factor: 4.964

7.  MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention.

Authors:  Robert Belvís; Pablo Irimia; Patricia Pozo-Rosich; Carmen González-Oria; Antonio Cano; Javier Viguera; Belén Sánchez; Francisco Molina; Isabel Beltrán; Agustín Oterino; Elisa Cuadrado; Angel Gómez-Camello; Miguel Alberte-Woodward; Carmen Jurado; Teresa Oms; David Ezpeleta; Javier Díaz de Terán; Noemí Morollón; Germán Latorre; Marta Torres-Ferrús; Alicia Alpuente; Raquel Lamas; Carlos Toledano; Rogelio Leira; Sonia Santos; Margarita Sánchez Del Río
Journal:  J Headache Pain       Date:  2021-07-17       Impact factor: 7.277
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.